When a regulator approves the first-ever treatment for a disease, my first instinct is relief for the families who have waited years for exactly this. Then I read the label, and the relief turned into something more complicated. The FDA has approved Emcitate (tiratricol) for MCT8 deficiency, and the press headline calls it the first treatment for the disease. The approved indication says something much narrower: it treats peripheral thyrotoxicosis, the racing heart and the metabolism burning itself down. It does not treat the part of this disease that any parent of an MCT8 child would name first.

MCT8 deficiency, also called Allan-Herndon-Dudley syndrome, comes down to a single broken transporter. Picture MCT8 as a doorman. The active thyroid hormone, T3, does not just drift into cells; certain cells need this particular doorman to let it in, and the cells that lean on him hardest are neurons and the barrier that guards the brain. Break the doorman and the developing brain is locked out of the one hormone it cannot build for itself. The gene sits on the X chromosome, so the disease overwhelmingly strikes boys, though a 2025 paper documented affected females too. Affected boys are born floppy and, as the clinical reviews describe, grow up unable to sit or walk on their own, with little or no speech and profound intellectual disability.

I had to read the next part twice. The T3 that cannot get through the brain’s door does not vanish. It has nowhere to go, so it builds up in the blood and pours into every tissue that uses a different door: the heart, the liver, the muscles. Those organs drown in thyroid hormone while the brain starves. Wait, why would one hormone cause famine in one room of the body and a flood in the next? Because the door is cell-type specific, and only the brain’s is broken. The flood is what wears the body down over time. A natural-history analysis in the Journal of Clinical Endocrinology & Metabolism puts hard numbers on it: a median life expectancy of about 35 years, roughly 30 percent of affected children dying in childhood, with thyrotoxic cardiomyopathy and sudden death driving the toll. Failure to reach a normal body weight between ages 1 and 3 is one of the strongest predictors of who dies.

So a drug that puts out that flood is not a small thing. It is worth celebrating.

What tiratricol does is almost elegant. It is a T3 look-alike, close enough that the body’s tissues respond to it, but built so it does not need the broken doorman to get inside a cell; it slips in through other transporters. That lets it occupy the receptors a flooded heart is drowning in and pull down the toxic pile-up of natural T3 in the blood. In the pivotal Triac Trial I, published in The Lancet Diabetes & Endocrinology in 2019, 46 patients with a median age of about 7 took an individually adjusted dose for up to a year. Their elevated serum T3 came down toward normal, their body weight improved, their heart rate fell, and the premature atrial contractions and high blood pressure eased. On the body’s terms, the drug did what the biology predicted.

But read that median age again: 7. That is where the hope runs into the biology, because the same molecule that sneaks past the doorman can reach the brain too, which is exactly why you would want it to rescue neurodevelopment. It mostly does not, and the reason is timing, not chemistry. Thyroid hormone does its foundational work on the brain in utero and in the first months of life. Miss that window and the wiring is already laid down wrong. Triac Trial I showed no significant improvement in the children’s neurodevelopmental scores after a year on the drug. The only flicker of neurological benefit turned up in the children treated youngest, under age 4, and even there it was a trend, not restored cognition. The field’s own comparison is congenital hypothyroidism: catch it at birth and you can prevent the damage; catch it at 7 and you are managing the aftermath.

They already ran the early trial

Egetis had already run the trial built to answer exactly the early-treatment question. Triac Trial II enrolled boys who were 30 months old or younger, about as early as these children get caught, after animal work suggested tiratricol could fully rescue the brain when given right after birth. In June 2024 the company reported that the trial did not meet its co-primary neurodevelopmental endpoints: the gross-motor and Bayley infant-development scores showed no statistically significant improvement over historical controls. What the trial did confirm, again, was that serum T3 fell durably in every child. Treated as infants, these boys got the peripheral fix and no measurable rescue of the brain.

This is why the name matters, and why “first treatment for MCT8 deficiency” is not a fair description of what a family is getting. To the people who live with this disease, the disease is the neurological devastation, and that is the one thing no version of this drug has been shown to touch. The drug treats the thyrotoxicosis. Both matter, they are not the same thing, and the gap between the press-release headline and the label is where the spin hides. It helps to know who shaped the framing. The sponsor is Egetis Therapeutics, which calls the approval a turning point for the MCT8 community. Egetis provided editorial support for that natural-history paper, which endorses the 2024 guideline recommending tiratricol as long-term therapy for all patients. The drug carries the full expedited stack: orphan, rare-pediatric-disease, fast-track and breakthrough designations plus priority review. The label’s side effects are comparatively mild: diarrhea, vomiting, rash and excessive sweating.

So where does that leave the promise of catching it early? Thinner than the approval suggests. The preclinical rescue happened when animals were dosed right after birth; the human infants in Trial II were enrolled up to 30 months, and even that may be past the window that matters. MCT8 deficiency is not on standard newborn-screening panels, so most boys are diagnosed long after any developmental window has shut. The honest state of the science is that we can reliably control the thyrotoxic flood at any age, and we cannot yet point to proof that the drug protects the brain at any age, infancy included. That is not a reason to stop finding these children early. It is a reason to be precise about what finding them early actually buys.

If this were my newborn son, unusually floppy, slow to hold his head up, with labs showing that telltale high-T3, low-T4 pattern, I would not wait for a specialist referral to wind through the system; I would ask for the SLC16A2 genetic test now. Not because there is a proven drug to save his brain, because there is not, but because the flood is what shortens these boys’ lives, it is treatable, and I would want it controlled from the first month rather than the seventh year.

Sources

  1. FDA – FDA Approves First Treatment for MCT8 Deficiency (Emcitate/tiratricol), Sept. 2026
  2. The Journal of Clinical Endocrinology & Metabolism – Thyrotoxicosis in MCT8 deficiency (natural history; Egetis editorial support), 2026
  3. The Lancet Diabetes & Endocrinology – Groeneweg et al., Triac Trial I, phase 2 open-label trial in MCT8 deficiency (2019)
  4. Egetis Therapeutics – Topline results of the Phase 2 Triac Trial II (co-primary neurodevelopmental endpoints not met), June 2024 (company announcement)
  5. ClinicalTrials.gov – Triac Trial II in MCT8 Deficiency Patients (NCT02396459)
  6. Frontiers/PMC – Monocarboxylate Transporter 8 Deficiency: From Pathophysiological Understanding to Therapy Development (review)
  7. The Journal of Clinical Endocrinology & Metabolism – MCT8 Deficiency in Females (2025)
  8. Egetis Therapeutics – U.S. FDA Approval of Emcitate (tiratricol) announcement (company announcement), Sept. 2026